Estradiol Represses the GD₃ Synthase Gene ST8SIA1 Expression in Human Breast Cancer Cells by Preventing NFκB Binding to ST8SIA1 Promoter

Marie Bobowski¹, Audrey Vincent¹,²,³, Agata Steenackers¹,²,³, Florent Colomb¹,²,³, Isabelle Van Seuningen¹,²,⁴, Sylvain Julien¹,²,³, Philippe Delannoy¹,²,³,⁴

¹ Université Lille Nord de France, Lille, France, ²Université des Sciences et Technologies de Lille (USTL), Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), Villeneuve d’Ascq, France, ³Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 8576, Villeneuve d’Ascq, France, ⁴Institut National de la Santé et de la Recherche Médicale (INSERM), Jean Pierre Aubert Research Center, Lille, France

Abstract

Recent data have underlined a possible role of GD₃ synthase (GD3S) and complex gangliosides in Estrogen Receptor (ER) negative breast cancer progression. Here, we describe the main transcript of the GD3S coding gene ST8SIA1 expressed in breast tumors. We characterized the corresponding core promoter in HS578T breast cancer cells and showed that estradiol decreases ST8SIA1 mRNA expression in ER-positive MCF-7 cells and ERα-transfected ER-negative HS578T cells. The activity of the core promoter sequence of ST8SIA1 is also repressed by estradiol. The core promoter of ST8SIA1 contains two putative Estrogen Response Elements (ERE) that were not found to be involved in the promoter activity pathway. However, NFκB was shown to be involved in ST8SIA1 transcriptional activation and we demonstrated that estradiol prevents NFκB to bind to ST8SIA1 core promoter in ERα expressing breast cancer cells by inhibiting p65 and p50 nucleus localization. The activation of NFκB pathway in ER-negative tumors, due to the absence of estradiol signaling, might explain the overexpression of GD₃ synthase in this tumor subtype.

Introduction

Gangliosides are glycosphingolipids carrying one or several sialic acid residues, and are essential compounds of the plasma membrane, by exposing their glycan moiety to the extracellular domain. They are enriched together with other phospholipids and cholesterol in lipid microdomains named “glycosynapses”, where they can modulate cell signaling, leading to changes in cellular phenotype [1,2]. Glycosphingolipids from ganglio-series represent the main class of gangliosides and are usually classified in four series according to the presence of 0 to 3 sialic acid residues linked to lactosylceramide [3,4].

While normal tissues usually express 0- and a-series gangliosides, gangliosides from b- and c-series are mostly expressed during embryogenesis and in the central nervous system in healthy adults, where they play a key role in cell-cell interaction, differentiation and growth [5,6]. In parallel, complex gangliosides such as GD₃, GT₃ or GD₂ have been found over-expressed in human tumors of neuroectoderm origin such as melanoma, glioblastoma and neuroblastoma [7-9]. They play a functional role in tumor growth and metastasis by mediating cell proliferation, migration, adhesion and angiogenesis [10]. Complex gangliosides have also been used as target molecules for cancer immunotherapy, such as GD₂ in melanoma [11,12] and GD₁₂ in neuroblastoma [13,14].

In normal breast tissues, complex gangliosides are absent or expressed at very low level. However GD₃, 9-O-acetyl-GD₂ and 9-O-acetyl-GT₂ are oncofetal markers in invasive ductal breast carcinoma (IDC) [15]. Clinical studies have also shown that high expression of ST8SIA1, the gene coding the GD₃ synthase (GD3S), is associated with Estrogen Receptor (ER) negativity and high histological grade of breast tumors [16,17]. The GD3S is the only a₂,₃-sialyltransferase that synthesizes the disialoganglioside GD₃ from its precursor G₃S [18,19]. GD3S is therefore the key enzyme controlling the biosynthesis of complex gangliosides from b- and c-series.

In order to determine the role of complex gangliosides in breast cancer progression, we have previously induced GD₃S over-expression in ER-negative MDA-MB-231 breast cancer cell line [20]. The resulting cellular model, MDA-MB-231 GD₃S⁺, displayed a proliferative phenotype in absence of exogenous growth factor. This proliferative capacity of MDA-MB-231 GD₃S⁺ clones directly proceeded from the constitutive activation of c-Met Tyrosine Kinase Receptor [21] and we recently showed that the ligand-independent activation of c-Met was due to the expression of GD₁₂ ganglioside at the cell surface of GD₃S⁺ clones.
[22]. Altogether, these data strongly suggest a possible role of GD3S and complex gangliosides in ER-negative breast cancer progression. Moreover, high GSTP expression was recently detected in breast cancer stem cells that was shown to be critical for mammosphere formation and tumor initiation [23]. Notably, GD3S but not GSTL/GSTD syntheses correlated with GSTD2 expression and GD3S knockdown reduced cancer stem cells properties and tumor formation.

To elucidate the molecular mechanisms leading to over-expression of GD3S in breast cancer, we have undertaken the study of the transcriptional regulation of the GD3S coding gene, ST8SIA1, in breast cancer cells. ST8SIA1 is located on chromosome 12, in p12.1-p12.2 locus and consists in five coding exons spanning over 135 kbp [24]. Several reports have described the 5'-untranslated region (5'-UTR) of ST8SIA1 in melanoma [24,25], glioblastoma [26] and neuroblastoma [27] cell lines, showing a unique transcript with transcription start sites (TSS) located 400 to 500 bp upstream the initiation codon on the first exon. In this study, we described the main ST8SIA1 transcript expressed in breast cancer tumors and cell lines and we characterized the core promoter of this gene. We also showed that estradiol repressed endogenous ST8SIA1 mRNA expression as well as ST8SIA1 core promoter activity by preventing NFκB binding in two human breast cancer cell lines expressing Estrogen Receptor alpha (ERα).

Materials and Methods

Breast Cancer Tumor Collection

20 tissue samples of IDC with ER-negative status (numbered 132 to 152) were provided by the Guy’s and St Thomas’s NHS foundation, Guy’s Hospital, London, United Kingdom. The NHS Research Ethics Committee (REC) approved the use of these tissues (ref: 07/H0804/131; HTA licence ref: 12121).

Cell Culture

The human breast cancer cell line Hs578T [28] was kindly provided by Dr Van Slambrouck (New Mexico Institute of Mining and Technology, NM, USA). The human breast cancer cell line MCF-7 was obtained by the ATCC (Rockville, MD, USA). Both cell lines were routinely grown in Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose, Ultragate insulin 1 supplemented with 10% fetal calf serum and 100 μg/mL penicillin-streptomycin (Lonza, Verviers, Belgium), at 37°C in an atmosphere of 5% CO2. When necessary, cells were grown for 48h in DMEM without phenol-red containing 10% charcoal-stripped serum (Invitrogen, Carlsbad, CA, USA) before treatment 24 or 12 h with 17β-estradiol (Sigma Aldrich, Lyon, France) and/or Tamoxifen (Tamoxifen, Sigma) and/or TNF (Tumor Necrosis Factor) or ethanol as vehicle.

5'-Rapid Amplification of cDNA Ends (5'-RACE)

The 5'-RACE system for Rapid Amplification of cDNA ends (Invitrogen) was used according to the protocol provided by the manufacturer. Initial reverse transcription was performed with the RT primer (annealing to the ST8SIA1 sequence) using 4 μg of total RNA. After synthesis of the first strand cDNA, nested PCR was performed using Platinum® Taq DNA polymerase (Invitrogen). GSP1/Anchor primer and GSP2/AUAP primer pairs were used for first and second PCR, respectively. PCR products were size-separated by Agarose gel electrophoresis, subcloned into pCR2.1-TOPO vector (Invitrogen) and sequenced by Genoscreen (Lille, France).

Plasmids Construction and Mutagenesis

ESR1 open reading frame was amplified from MCF-7 cells cDNA with the primer pair ERαNhe1 and ERαKpn1 (Table 1). The PCR product was digested by Nhe1 and Kpn1 and cloned into the pcDNA3.1 expression vector (Invitrogen). The resulting plasmid was designed pcDNA-ERα. pCMV-p50 and pCMV-p65 vectors, expressing p50 and p65 NFκB subunits respectively, were previously described [29].

Genomic DNA of Hs578T cells was prepared with Nucleospin Extract II kit (Macherey-Nagel, Duren, Germany) following manufacturer’s instructions. The genomic sequence located between −2307 bp and the ATG site was amplified by PCR using the primer pair P1Nhe1 and P2Xho1 (Table 1). The PCR product was cloned into the pCR2.1-TOPO vector (Invitrogen). The promoter sequence was then isolated by digestion of the vector using Nhe1 and Xho1 restriction sites. The purified fragment was sub-cloned into pGL3-Enhancer vector (Promega, Madison, USA) upstream of the firefly luciferase gene at Nhe1/Xho1 sites. The resulting plasmid was designed pGL3(−2307/+1). Truncated promoter constructs were generated by enzymatic digestions, ends blunting and ligation (Table 2). All plasmid constructs were sequenced to ensure the absence of mutation (Genoscreen, Lille, France).

Mutations with base substitutions at Estrogen Response Element (ERE) binding sites on pGL3(−923/+565) were obtained using a Quick Change mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s protocol, using the oligonucleotide primers shown in Table 1. The plasmid mutations were verified by sequence analysis.

RNA Extraction, cDNA Synthesis and Quantitative PCR

Total RNA from tumor samples or breast cancer cells was extracted using the Nucleospin RNA II (Macherey-Nagel). RNA quality was checked using the Agilent Bioanalyzer 2100 (Agilent technologies, Santa Clara, CA, USA). Total RNA was reverse transcribed using Affinity script qPCR cDNA Synthesis kit (Agilent) according to the protocol provided by the manufacturer.

Primers sequences (Eurogentec, Seraing, Belgium) used for the PCR reactions are given in Table 1. Quantitative real-time Polymerase Chain Reaction (qPCR) was performed using the Mx3005p Quantitative System (Stratagene) as previously described [20]. Briefly, 40 cycles were performed according to the following program (94°C for 30 s, 60°C for 30 s, and extension at 72°C for 30 s). The analysis of amplification was performed using the Mx3005p software. For each primer pair, the specificity of the amplification was checked by recording the dissociation curves, visualizing the amplified products in Agarose-gel electrophoresis and sequencing of the products. HPRT or RPLP0 genes were used to normalize the expression of transcripts of interest. Relative quantification was performed using the method described by Pfaff, that takes in account the efficiency of each sequence amplification [30].

Bioinformatic Analysis

In silico analysis of the promoter was performed with BLAST analysis of the human genome of the NCBI database. Multiple sequence alignments were performed with the Multalin program (http://multalin.toulouse.inra.fr/multalin/multalin.html). The core promoter sequence was analyzed with MatInspector 8.0 (www.genomatix.de) using TRANSAC matrices 8.4 [31] with “core similarity: 0.95” and “matrice similarity: optimized”.

PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e62559

Estradiol-Induced Repression of GD3 Synthase
Table 1. Primers used for 5’-RACE, qPCR and plasmid constructions.

| Primer               | Sequence                              |
|----------------------|---------------------------------------|
| RT primer            | 5’-CACAGGCACCTCTCTCTT-3’               |
| GSP1                 | 5’-CCACATTTCCACACCCGCGATT-3’          |
| GSP2                 | 5’-TTGTCTTGAGGAAAGAAGTAGTGG-3’        |
| Anchor primer        | 5’-GGGACCGGTGTCGACTAGTG-3’            |
| AUAP                 | 5’-GGGACCGGTGTCGACTAGTG-3’            |
| GD3ESE4-E5 forward   | 5’-CCACGATACTGCGGCT-3’                |
| GD3ESE5-E6 reverse   | 5’-ACCTCAAGATGCTTGTCTC-3’             |
| GD3SE1-E2 forward    | 5’-AACGAGAAAGAGTCTGCG-3’              |
| GD3SE1-E2 reverse    | 5’-CGTCATACACATGCTTCT-3’              |
| PS2 forward          | 5’-TAGACACTTCTGAGGATTAGTG-3’          |
| PS2 reverse          | 5’-GCGATCGTCTTGTGAGC-3’               |
| RPLP0 forward        | 5’-GTATGGTGCAGTCGATCAAGACT-3’         |
| RPLP0 reverse        | 5’-GTATGGTGCAGTCGATCAAGACT-3’         |
| HPRT forward         | 5’-GCCAAGCTTTTGATGATT-3’              |
| HPRT reverse         | 5’-CCTCTATCTTAGGTTGTATTTTG-3’         |
| ChIP-NFκB forward    | 5’-AGAAGACGCGGACAGCAAGG-3’            |
| ChIP-NFκB reverse    | 5’-AGAAGAACCTCTCCTCATCAGT-3’          |
| P1Nhe1 forward       | 5’-CTCCGTCTGATCTTTGAGGAAGAGAAGAAACAGC-3’ |
| P2Xho1 reverse       | 5’-CAAATTCTGAGGCTTGTCTGAT-3’          |
| ERαNhe1 forward      | 5’-GGGCTAGGCCCATGACATGACCCTGAC-3’     |
| ERαKpn1 reverse      | 5’-GGGGTACCATGACGAGGATTACCTGAG-3’     |
| muERE1 forward       | 5’-TGTCGTCGGCTTTCTCCAAAGAGATAGCAAAGTGGAGG-3’ |
| muERE1 reverse       | 5’-CCCTCCTGCTGCTCTTGGAGATACCCGAGAC-3’ |
| muERE2 forward       | 5’-GGGGGAGGGGAGGGAGAGAGACGATTTCCACAATCC-3’ |
| muERE2 reverse       | 5’-GGGATGGGCTATTAGCTGTCGCTCCTGCCTGCC-3’ |
| muERE1 reverse       | 5’-CCCTCCTGCTGCTCTTGGAGATACCCGAGAC-3’ |
| muERE2 forward       | 5’-GGAGGGGAGGGGAGGGACGACGATTCCACAATCC-3’ |
| muERE2 reverse       | 5’-GGGATGGGCTATTAGCTGTCGCTCCTGCCTGCC-3’ |
| muNFκB forward       | 5’-GGGGGAGGGGAGGGAGGGACGACGATTCCACAATCC-3’ |
| muNFκB reverse       | 5’-GGTGGAAATCCAGGTTTCTTCTCTCCTGCC-3’  |

1 Previously used by Kang et al. [25].
2 Provided by Invitrogen.
3 Designed using the NCBI primer design software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).
4 Designed using the QuickChange primer design software (http://labtools.stratagene.com/QC).
5 Restriction site sequences inserted for cloning are underlined and the mutated nucleotides in primers used for site directed mutagenesis are in bold.

Estradiol-Induced Repression of GD3 Synthase

Transient Transfection and Luciferase Assay

Hs578T cells (80% confluence) were transfected using lipofectamine (Invitrogen) according to the manufacturer’s instructions, with 1.5 µg of pGL3 construction and 20 ng of control Renilla plasmid in UltraMEM medium (Invitrogen). When necessary, 2 µg of pcDNA-ERα and 1 µg of pCMV-p50 and pCMV-p65 expression vectors were added to the transfection mix. After 6 h, the medium was replaced by fresh culture medium containing 10% FCS and further incubated for 48h. Cells were then washed with Phosphate Buffered Saline (PBS), lysed with Passive Lysis Buffer (PLB, Dual Luciferase Reporter Assay System, Promega, Madison, USA) and 20 µL of lysate were used for luciferase Reporter Assay System. Luminescence was measured with the Centro luminometer (Berthold Technologies, Bad Wildbad, Germany).

Nuclear Protein Extraction and Western Blotting Analysis

ERα expressing Hs578T and MCF-7 cells transfected or not with pCMV-p50 and pCMV-p65 were lysed on ice in a hypotonic buffer (Hepes 10 mM, MgCl2 1.5 mM, KCl 10 mM, pH 7.9) supplemented with 0.125% NP40 and protease cocktail inhibitors (Roche, Meylan, France). The lysate was centrifuged 5 min at 10,000 g. The pellet corresponding to the nuclear fraction was lysed with hypertonic buffer (Hepes 20 mM, MgCl2 1.5 mM, EDTA 0.2 mM, NaCl 0.5 M, glycerol 25%, pH 7.9) supplemented with protease cocktail inhibitors on ice during 2 h. The protein concentration was determined with the Micro BCA™ Protein Assay Reagent kit (Pierce, Rockford, IL, USA). 40 µg of total proteins were boiled for 10 min in reducing Laemmli sample buffer and resolved by SDS-PAGE on 8% or 12% mini-gels (Bio-Rad, Richmond, USA). After transfer onto a nitrocellulose membrane (80 µm overnight), blocking was performed using Tris Buffer Saline (TBS) containing 0.05% Tween 20 and 5% (w/v) non-fat dried milk for 1 h at room temperature (RT). Incubations
with anti-p65 (sc-7151x), anti-p50 (sc-1190x) mAbs (Santa Cruz Biotechnology Inc., Europe) and anti-histone H2B (07-371) mAb (Millipore, Billerica, USA) were performed 1 h at RT in TBS, 0.05% Tween 20 and 5% (w/v) non-fat dried milk. Cells were scraped off and collected by centrifugation at 700 g for 5 min at 4°C, before being resuspended in lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl₂, and 0.1% Nonidet P40) plus protease inhibitors and incubated for 10 min on ice. Chromatin was sheared with the Bioruptor system (Diagenode). The extracts were sonicated for 10 pulses of 30 s each with ice. Chromatin was sheared with the Bioruptor system (Diagenode), the extracts were sonicated for 10 pulses of 30 s each with ice. Chromatin was sheared with the Bioruptor system (Diagenode), the extracts were sonicated for 10 pulses of 30 s each with ice.

Promoter Activity of the 5'-flanking Region Upstream the GD3S T1 Transcript

To determine the core promoter sequence of the T1 transcript, the genomic sequence located between −2307 bp and the ATG site in E1 was cloned into the pGL3basic upstream the luciferase gene and named pGL3(−2307/+1). This plasmid and the 5′- or 3′-deleted constructs, were transfected into Hs578T cells for luciferase assays. The results presented in Fig. 2 showed a 2.9-fold increase of luciferase activity for the full length plasmid pGL3(−2307/+1) compared to pGL3basic used as baseline control. By comparison, all constructs lacking the −565/+1 region showed increased activities with maximal promoter activities for pGL3(−1117/−563) and pGL3(−923/−563) constructs (7.4- and 7.0-fold, respectively). In parallel, 5′ truncations of various length induced decreased luciferase activity with pGL3(−565/+1) and pGL3(−335/+1) constructs showing almost no activity compared to pGL3basic (1.2- and 1.3-fold, respectively). Together, these data suggest the existence of a core promoter region of GD3S within the sequence −923/−565 and a negative regulation region within −565/+1.

Bioinformatics’ Analysis of T1 Core Promoter Region

The putative core promoter sequence −923/−565 was analyzed with MatInspector software with “core similarity: 0.95” and “matrix similarity: optimized”. This analysis did not reveal any canonical TATA or CAAT boxes as previously reported by others [24]. However, a large number of putative binding sites for general (e.g. SP1) and specific transcription factors were retrieved. Positions of putative transcription factors related to breast cancer are presented in Table 3. Notably, two putative Estrogen

| Digestion | Position | Vector name |
|-----------|----------|-------------|
| NheI, XhoI | −2307/+1 | pGL3(−2307/+1) |
| AelI, XhoI | −1779/+1 | pGL3(−1779/+1) |
| HindIII, XhoI | −1419/+1 | pGL3(−1419/+1) |
| SacI, XhoI | −1117/+1 | pGL3(−1117/+1) |
| AlwNI, XhoI | −923/+1 | pGL3(−923/+1) |
| BstXI, XhoI | −565/+1 | pGL3(−565/+1) |
| FspI, XhoI | −335/+1 | pGL3(−335/+1) |
| NheI, BstXI | −2307/−565 | pGL3(−2307/−565) |
| AelI, BstXI | −1779/−565 | pGL3(−1779/−565) |
| HindIII, XhoI | −1419/−565 | pGL3(−1419/−565) |
| SacI, XhoI | −1117/−565 | pGL3(−1117/−565) |
| AlwNI, BstXI | −923/−565 | pGL3(−923/−565) |

Table 2. Reporter plasmid constructions.
Response Element (ERE) were found at position -867/-844 (ERE1) and -783/-760 (ERE2).

Estradiol Represses Endogenous ST8SIA1 Transcripts in ER-positive MCF-7 and in ER-negative ERα-transfected Hs578T Cells

Given that ST8SIA1 is over-expressed in ER-negative breast tumors [16] and that its core promoter contains two putative sites...
for ERα binding, we investigated the effect of estradiol on ST8SIA1 mRNA expression in breast cancer cell lines MCF-7 and Hs578T.

ST8SIA1 expression was analyzed by qPCR in ER-positive MCF-7 cells treated with estradiol (10^-10 M) and/or Tamoxifen (10^-6 M).

Figure 2. Promoter activity of the 5’ flanking region of GD3S T1 transcript in Hs578T cells. (A) Location of the restriction sites used to generate the different deletions of the genomic sequence between -2307 and the ATG site (+1) in E1 exon. The positions of EREs and NFkB binding site in the core promoter are indicated. Arrowheads show the position of TSS from -345 to -20 bp upstream the ATG. (B) On the left, schematic representation of the different constructs inserted in pGL3 basic upstream the luciferase gene. Luc indicates the Firefly luciferase coding sequence. On the right, luminescence detected in luciferase assays. Transfection efficiencies were normalized with the co-transfected plasmid expressing Renilla luciferase and luciferase activities are expressed compared to empty pGL3 basic activity. The data are means +/- S.D. of n = 3 experiments.

doi:10.1371/journal.pone.0062559.g002

Table 3. Predicted transcription factors binding sites in -923/-565 core promoter and their relevance in breast cancer.

| Transcription factor | Core sequence | Position | Strand | Involvement in breast cancer |
|----------------------|--------------|----------|--------|-------------------------------|
| WT1 (Wilm’s tumor 1) | CGGG         | -914/-898 | +      | Involved in proliferation and differentiation [47]. Over-expressed in ER-negative tumors [48] |
|                      | TGGG         | -793/-777 | -      |                                |
|                      | AGGG         | -783/-767 |        |                                |
| c-Myb                | CAAC         | -906/-892 | -      | Oncogene. Stimulates cell proliferation [49] |
|                      | TAAC         | -693/-679 | +      |                                |
| NFkB                 | GGGG         | -777/-762 | +      | Downregulated by ER signaling [43] |
| ERE (Estrogen Response Element) | AAGG | -867/-844 | +      | Regulation of estrogen-responsive genes [50] |
|                      |              | -783/-760 |         |                                |
| E2F2                 | GCCG         | -849/-833 | +/-    | Regulated by estradiol [51] |
|                      |              | -710/-694 | +/-    |                                |
| KLF15 (Kruppel Like Factor 15) | GGGG | -789/773 | +      | Regulates estradiol-induced proliferation [52] |
| NFAT (Nuclear Factor of Activated T cells) | GGAA | -770/-752 | +      | Pro-invasive and pro-migratory [53] |
|                      |              | -589/-571 | +/-    |                                |
| ETS-1                | GGAA         | -723/-703 | +      | Associated to invasive phenotype [54] |

Table 3 was generated using the following code:

```"
for 24h. \textit{PS2}/\textit{TFF1} (Trefoil Factor 1) gene, known to be up-regulated by estradiol [33] was similarly analyzed to control the estradiol responsiveness of the treated cells. As shown in Fig. 3A, estradiol expectedly increased \textit{PS2} expression while \textit{ST8SIA1} expression decreased significantly (about 4.5 fold). TAM treatment abolished the increased \textit{PS2} expression but has no antagonistic effect on estradiol-mediated \textit{GD3S} mRNA repression. Similar experiment was performed in ER-negative Hs578T cells transfected or not with the pcDNA-\textit{ER} \textit{\alpha} vector 24h before estradiol treatment. Estradiol had no significant effect on the expression of \textit{PS2} or \textit{ST8SIA1} in mock-transfected Hs578T cells (Fig. 3B). In contrast, in Hs578T exogenously over-expressing \textit{ER} \textit{\alpha}, estradiol induced an increase of \textit{PS2} expression as well as a slight but significant decrease of \textit{ST8SIA1} expression. Taken together, our results demonstrate that estradiol represses \textit{ST8SIA1} expression in an \textit{ER} \textit{\alpha} dependent manner.

**The Core Promoter Activity is Inhibited by Estradiol through an ERE-independent Manner Involving NF\text{k}B Transcription Factor**

To demonstrate the role of EREs found in the core promoter in the estradiol-mediated \textit{ST8SIA1} regulation, we analyzed the activity of the promoter sequence \(-923/-565\) in estradiol treated Hs578T cells transfected or not with pcDNA-\textit{ER} \textit{\alpha}. As shown in Fig. 4A, estradiol had no significant effect on the core promoter activity in mock-transfected Hs578T cells (control). In parallel, \textit{ER} \textit{\alpha} expression allowed a significant decrease of the luciferase activity (50%) in estradiol treated cells. A similar fold of repression was obtained for the pGL3(\(-1117/-563\)) construct (data not
However, site-directed mutagenesis of either one or both putative ERE on pGL3(−923/−565) construct did not suppress the repressive action of estradiol (Fig. 4A). This result suggests that the ERE sites are not involved in ER signaling and that estradiol exerts an indirect effect on the ST8SIA1 promoter activity. Lee and coworkers described a functional NFκB binding site on ST8SIA1 promoter in melanoma cells [25,27] that we also confirmed by bioinformatic analysis at position −2777/−2762 (Table 3). As shown in Fig. 4A, the mutation of NFκB binding site led to a significant decrease of luciferase activity (30%), demonstrating NFκB to be involved in ST8SIA1 promoter activity in breast cancer cells. Notably, directed mutagenesis of others predicted transcription factors binding sites described in Table 3 have no effect on the activity of the core promoter (data not shown).

Moreover, p50 and p65 expression vectors transfection or TNF treatment, both inducing an increase of p50 and p65 NFκB subunits in the nucleus (Fig. 4B), resulted in a 2-fold increase of luciferase activity (Fig. 4A). Furthermore, we showed that estradiol inhibited the NFκB-mediated increase of ST8SIA1 promoter activity in Hs578T-ERα cells (Fig. 4A). This could be explained by the inhibitory effect of estradiol on p50 and p65 nuclear localization (Fig. 4B). Altogether, these data show the role of NFκB in transcriptional activation of ST8SIA1 promoter in breast cancer cells and suggest that estradiol inhibits NFκB-mediated activation by preventing p50 and p65 NFκB subunits translocation into the nucleus.

### Estradiol Decreased Endogenous NFκB Binding to ST8SIA1 Promoter in ERα-Expressing Breast Cancer Cell Lines

To confirm that NFκB directly acts on ST8SIA1 promoter, ChIP experiments were performed using Hs578T expressing ERα

---

**Figure 4. Estradiol-mediated repression of ST8SIA1 promoter activity do not involve ERE element but NFκB transcription factor.**

(A) Effect of mutations of ERE and NFκB putative sites on −923/−565 core promoter activity. After 48h of culture in steroid-free medium, Hs578T were transfected with pGL3(−923/−565), either native or mutated on ERE binding sites, pcDNA-ERα and/or pCMV-p65 and pCMV-p50. Transfection with empty expression vectors was used as negative controls. The following day, cells were treated for 12 h with 10−10 M estradiol and/or 40 ng/mL TNF. On the left: schematic representation of the sequence transfected in Hs578T cells. Black circles indicate the mutated ERE sequences and black triangle indicates the mutated NFκB site. On the right: relative luciferase activity of the core promoter in Hs578T cells treated or not with 10−10 M estradiol. Transfection efficiencies were normalized with the co-transfected plasmid expressing Renilla luciferase and reported to the luciferase activity in cells transfected with native pGL3(−923/−565) treated with vehicle. Vehicle: 0.1% ethanol. Each bar represents the mean ± S.D. of n=3 experiments. *: p<0.05. (B) Effect of estradiol on p50 and p65 NFκB subunits nuclear expression in ERα expressing Hs578T and MCF-7 cells. Nuclear proteins extracted from ERα-transfected Hs578T and MCF-7 cells treated as previously described in A were used for immunoblotting with anti-p50 or anti-p65 mAbs. Histone H2B expression was used as a loading control.

doi:10.1371/journal.pone.0062559.g004
and MCF-7 cells treated with TNF, in absence or in presence of estradiol (Fig. 5). We found that the region −868/−665 of the ST8SIA1 promoter, encompassing the −777/−762 NFκB binding site, was enriched for p65 over the negative control IgG both in Hs578T-ERα and MCF-7 cell lines, showing that p65 directly binds this promoter region in these cells. Estradiol treatment led to a significant decrease of p65 binding in both Hs578T-ERα and MCF-7 cell lines. As shown in Fig. 6, the loss of NFκB binding on ST8SIA1 promoter is associated with a decrease of endogenous ST8SIA1 mRNA expression in both MCF-7 and Hs578T-ERα cells. Furthermore, confirming the results obtained with the core-promoter constructs, TNF treatment of MCF-7 and Hs578T-ERα cells led to a 2.9- and 2.4-fold increase of ST8SIA1 mRNA expression, respectively, and estradiol treatment reverted this effect.

Discussion

In this paper, we determined that T1 is the major transcript of GD3S expressed in breast tumor tissues and we characterized the core promoter essential for transcription of GD3S in human breast cancer cells. In breast tumor tissues, the 5′-UTR of T1 transcript is shorter but similar to the one found in other cell lines [24–27]. Furthermore, we newly described minor transcripts as T2 and T3 with alternative first exon that lack initiation codon. Similar aberrant non-coding transcripts have recently been described in tumors and have been suggested to play functional roles in cancer progression and metastasis [34]. Interestingly, the core promoter we identified in breast cancer cells, between −923 and −565 upstream the initiation codon, overlaps with the core promoter found in melanoma (−833/−519) [24] and neuroblastoma (−1190/−690) [27] but not with the one found in glioblastoma (−1330/−1190) [26], suggesting a tissue-specific regulation of ST8SIA1.
In the present study, we show an ERα-mediated estradiol down-regulation of both endogenous GD3S mRNA and core promoter activity in breast cancer cells. This result fits well with a microarray analysis showing an inverse correlation between ST8SIA1 and ESR1 (coding ERα receptor) gene expression in invasive breast cancer primary tumors [16,17]. We therefore propose that high expression of GD3S in ER-negative tumors, due to the loss of ERα signaling, could increase complex gangliosides expression at the cell surface, and through this possibly enhance the aggressiveness of this tumor subtype [21,23].

Transcriptional regulation by steroid hormones has been showed for several sialyltransferases. For instance, ST3Gal III and ST6Gal I were demonstrated to be up-regulated and down-regulated respectively by estradiol in MCF-7 breast cancer cells [35]. Testosterone was also shown to up-regulate ST3Gal II expression, through epigenetic regulation involving NFκB, in prostate cancer cells [36].

TAM is an estradiol antagonist used to treat ER-positive breast cancer patients. It plays an active role in inhibition of breast cancer cells proliferation through repression of ERα responsive genes normally involved in cell proliferation [37]. Although TAM

![Figure 6. Estradiol reverses the TNF-mediated increase of ST8SIA1 mRNA expression in ER-positive MCF-7 and in ER-negative Hs578T expressing ERα. ERα-expressing Hs578T and MCF-7 cells were treated with 10⁻¹⁰ M estradiol and/or 40 ng/mL TNF for 12h. ST8SIA1 mRNA expression was determined by qPCR. Results were normalized to the expression of RPLP0 and reported to the expression of ST8SIA1 in cells treated with vehicle (0.1% ethanol). Data are means +/- SD of n ≥3 experiments. *: p<0.05 vs. untreated (vehicle). doi:10.1371/journal.pone.0062559.g006](image)

![Figure 7. Hypothetical mechanism of GD3S repression by estradiol. GD3S gene (ST8SIA1) is activated by the canonical NFκB pathway after TNF stimulation. In ER-positive breast cancer cells, GD3S expression is repressed by estradiol (E2)-ERα complex. Repression of NFκB transport to the nucleus could be achieved via the activation of PI3K [44]. doi:10.1371/journal.pone.0062559.g007](image)
treatment of Hs578T cells efficiently prevented the expression of PS2, a well characterized estradiol responsive gene, it did not compete with estradiol-induced ST8SIA1 repression. Reassuringly, our results suggest that TAM treatment of breast cancer patients is unlikely to induce the expression of possibly deleterious complex gangliosides via ST8SIA1 induction in ER-positive breast cancer tumors.

Although bioinformatics analysis indicate two ERE on the core promoter, site mutagenesis of these predicted EREs in Hs578T cells failed to confirm their cis-regulatory function in ST8SIA1 transcription. However, it was reported that estradiol-mediated down-regulation of gene expression can be classified in two groups according to the kinetic of their response to the hormone [38,39]. Early-down-regulated genes are often primary targets of estrogen receptor, while late-down-regulated genes require secondary factors for transcription [38]. In our cells, ST8SIA1 down-regulation was only observed after 8h of estradiol treatment (data not shown) suggesting ST8SIA1 to be indirectly regulated by estradiol (i.e. without direct binding of ERα to ST8SIA1 promoter).

A functional NFκB binding site at −777/−762 pb upstream the ATG was shown to be essential for ST8SIA1 transcription in melanoma cells [25,27]. NFκB is a transcription factor frequently activated in tumors that is involved in tumor growth, progression and resistance to chemotherapy [40]. In particular, activated NFκB is predominantly detected in ER-negative vs. ER-positive breast tumors [41,42]. Accordingly, several studies have shown that ERα can inhibit NFκB activity in an estradiol-dependent manner in various cell lines [43]. For example, estradiol was shown to prevent p65 activation and to inhibit its intracellular transport to the nucleus via the activation of PI3K. This effect is mediated by ERα and selectively activated in macrophages to prevent the inflammatory response [44]. It was also shown that estradiol inhibits TNF-induced NFκB activation in MCF-7 cells [45]. Here, we show that NFκB is involved in transcriptional activation of GD3S in both Hs578T-ERα and MCF-7 breast cancer cells and that estradiol represses GD3S expression by inhibiting p65 and p50 nucleus transport (Fig. 7). This could explain the higher expression of GD3S in ER-negative breast cancer cells and tumors, in which the effect of NFκB cannot be repressed by estradiol, leading to a higher amount of complex gangliosides that reinforce proliferative capacity of the tumor. Delineating the molecular mechanisms by which estradiol represses GD3S in breast cancer cells could provide new targets to inhibit complex gangliosides synthesis and potentially hamper ER-negative breast tumors aggressiveness. Potential therapeutic strategy targeting NFκB would prevent complex gangliosides expression in ER-negative breast tumors. Drugs that inhibit NFκB signaling have been identified and are currently undergoing clinical trials in combination with standard anti-tumor agents to achieve a better treatment of tumors and an increase in survival [46].

Acknowledgments
M.B. was recipient of a Canon Foundation fellowship. We also thank the Guy’s and St Thomas’ NHS foundation Trust for providing breast tumor tissues.

Author Contributions
Conceived and designed the experiments: SJ PD. Performed the experiments: MB AS FC AV. Analyzed the data: MB SJ PD IVS. Contributed reagents/materials/analysis tools: FC AS MB. Wrote the paper: PD MB SJ.

References
1. Hakomori Si S (2002) The glycosynapse. Proc Natl Acad Sci USA 99: 225–232. doi:10.1073/pnas.012548999.
2. Regina Todeschini A, Hakomori S (2008) Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta 1780: 421–433. doi:10.1016/j.bbaexp.2007.10.008.
3. Svennerholm L (1980) Ganglioside designation. Adv Exp Med Biol 125: 11.
4. Tettamanti G (2004) Ganglioside/glycosphingolipid turnover: new concepts. Biochim Biophys Acta 1670: 201–217.
5. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, et al. (1999) A vital role of ST8SIA1-regulatory function in transcription. J Biol Chem 274: 33871–33875. doi:10.1074/jbc.274.46.33871.
6. Regina Todeschini A, Hakomori S (2008) Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta 1780: 421–433. doi:10.1016/j.bbaexp.2007.10.008.
7. Bloch W, Takahashi M, Nakamura K, Inoue J, Nakamura S, et al. (2002) Biochemical modulation of bacterial-associated carbohydrate antigens: novel targets for cancer therapy. Am J Physiol Lung Cell Mol Physiol 287: L321–L327. doi:10.1152/ajplung.00037.2002.
8. Ohtsuki M, Nishimura T, Toyama H (2005) Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathol Appl Neurobiol 31: 97–104. doi:10.1111/j.1365–2990.2004.00742.x.
9. Saito M, Yu RK, Chen N (1983) Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun 127: 1–7.
10. Birklé S, Zeng G, Gao L, Yu RK, Aubry J (2003) Role of tumor-associated gangliosides in cancer progression. Biochimica 85: 455–463.
11. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, et al. (2004) Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10: 4717–4723. doi:10.1158/1078–0432.CCR-04–0145.
12. Lo ASY, Ma Q, Liu DL, Jhunghs RP (2010) Anti-GD2 chimeric Fv-C2DH-T cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 16: 2769–2780. doi:10.1158/1078–0432.CCR-10–0483.
13. Navid F, Santanna VM, Barfield RC (2010) Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 10: 200–209.
14. Yu AL, Gilman AL, Osakayak MF, London WB, Kreisman SG, et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isoretinoin for neuroblastoma. N Engl J Med 363: 1324–1334. doi:10.1056/NEJMoa091123.
15. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, et al. (1996) Gangliosides expressed in human breast cancer. Cancer Res 56: 5165–5171.
16. Ruckhaberle E, Rody A, Angels K, Gaertl R, von Minckwitz G, et al. (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingolipase 1 in breast cancer. Breast Cancer Res Treat 112: 415–425. doi:10.1007/s10549–008–9603–6.
17. Ruckhaberle E, Kern T, Rody A, Hanker L, Gaertl R, et al. (2009) Gene expression of ceramide kinase, galactosylceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol 135: 1005–1013. doi:10.1007/s00432–008–0536–6.
18. Nakaya J, Fukuda MN, Hirabayashi Y, Kanamori A, Nasaki R, et al. (1996) Expression cloning of a human GT3 synthase. GD3 AND GT3 are synthesized by a single enzyme. J Biol Chem 271: 3684–3691.
19. Cazet A, Grous-Degrove S, Teylaert B, Kwon K-M, Lehoux S, et al. (2009) GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. Biol Chem 390: 601–609. doi:10.1515/BC.2009.054.
20. Cazet A, Lefevbre J, Adrianoens E, Julien S, Bobowski M, et al. (2010) GD3 synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 8: 1526–1535. doi:10.1158/1535-7163.MCR-10–0362.
21. Cazet A, Bobowski M, Romhous V, Lefevbre J, Steenackers A, et al. (2012) The ganglioside GD3 initiates the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the GD3 synthase. Glycoconj J 29: 383–394. doi:10.1007/s10719–012–9507–5.
22. Batuila VL, Shi Y, Evans KW, Wang R-Y, Sparer El, et al. (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122: 2066–2078. doi:10.1172/JCI69373.
23. Furukawa K, Horie M, Okutomi K, Sugano S, Furukawa K (2003) Isolation and characterization of human GD2 synthase gene. Biochim Biophys Acta 1627: 71–78.
24. Furukawa K, Horie M, Okutomi K, Sugano S, Furukawa K (2003) Isolation and functional analysis of the melanoma specific promoter region of human GD3 synthase gene. Biochim Biophys Acta 1627: 71–78.
25. Kang N-Y, Kim C-H, Kim K-S, Ko J-H, Lee J-H, et al. (2007) Expression of the human C-MAP-NeuAcut3 alpha2,6-sialyltransferase (GD3 synthase) gene...
through the NF-kappaB activation in human melanoma SK-MEL-2 cells. Biochim Biophys Acta 1769: 622–630. doi:10.1016/j.bbapap.2007.08.001.

26. Dae H-M, Kwon H-Y, Kang N-Y, Song N-R, Kim K-S, et al. (2009) Isolation and functional analysis of the human globoside-specific promoter region of the human GD3 synthase (hST8Sia I) gene. Acta Biochim Biophys Sin (Shanghai) 41: 237–245.

27. Kwon H-Y, Dae H-M, Song N-R, Kim K-S, Kim C-H, et al. (2009) Valproic acid induces transcriptional activation of human GD3 synthase (hST8Sia I) in SK-N-RE(2)-C human neuroblastoma cells. Mol Cells 27: 113–118. doi:10.1007/s10059-009-0012-4.

28. Hackett AJ, Smith HS, Owens RB, Nelson-Rees WA, et al. (1977) Purification, cloning, and expression of a marine phosphophenolase that binds the kappa B motif in vitro identifies it as the homolog of the human heterogeneous nuclear ribonucleoprotein K protein. Description of a novel DNA-dependent phosphorylation process. J Biol Chem 269: 17626–17634.

29. Piaff MW (2003) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.

30. Quandt K, Frecq K, Karas H, Wingender E, Werner T (1995) MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23: 4878–4884.

31. Juncroche N, Velghe A, Ducouvier M-P, Copin M-C, Renes IB, et al. (2011) The mouse Muc3b mucin gene is transcriptionally regulated by thyroid transcription factor-1 (TTF-1) and GATA-4 transcription factors. FEBs J 278: 202–209. doi:10.1111/j.1742–4658.2010.07945.x.

32. Masakowski P, Breutnach R, Bloch J, Gannon F, Krust A, et al. (1982) Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895–7903.

33. Gibb EA, Yucic EA, Endeild KSS, Stewart GL, Loneragan KM, et al. (2011) Human cancer long non-coding RNA transcriptomes. PLoS ONE 6: e25915.

34. Hackett AJ, Smith HS, Owens RB, Nelson-Rees WA, et al. (1977) Purification, cloning, and expression of a marine phosphophenolase that binds the kappa B motif in vitro identifies it as the homolog of the human heterogeneous nuclear ribonucleoprotein K protein. Description of a novel DNA-dependent phosphorylation process. J Biol Chem 269: 17626–17634.

35. Peyrat JP, Recchi MA, Hebbbar M, Pawlokvi V, Horvitz I, et al. (2000) Regulation of sialyltransferase expression by estradiol and 4-OH-tamoxifen in the human breast cancer cell line. Nucleic Acids Res 28: 282–294. doi:10.1111/j.1742–4658.2010.07945.x.

36. Hatano K, Miyamoto Y, Mori M, Nimura K, Nakai Y, et al. (2012) Androgen-regulated transcriptional control of sialytransferases in prostate cancer cells. PLoS ONE 7: e31274. doi:10.1371/journal.pone.0031274.

37. Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19: 1535–1544. doi:10.1210/me.2004–0395.

38. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289–1297. doi:10.1038/ng1901.

39. Frasor J, Danes JM, Kimm B, Chang KCN, Lyttle CR, et al. (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562–4574. doi:10.1210/ en.2003–0567.

40. Prasad S, Ravindran J, Aggarwal BB (2010) NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336: 25–37. doi:10.1007/s11010–009–0267–2.

41. Biswas DK, Shi Q, Bally S, Strickland I, Ghosh S, et al. (2004) NF-kappaB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137–10142. doi:10.1073/ pnas.0403621101.

42. Zhou Y, Epenberger-Catorso S, Epenberger U, Benz CC (2005) The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12 Suppl 1: S37–46. doi:10.1677/erc.1.00977.

43. Kalaitzidis D, Gilmore TD (2005) Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 16: 46–52. doi:10.1016/j.tem.2005.01.004.

44. Ghisletti S, Media G, Maggi A, Vegezo E (2005) 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol 25: 2957–2968. doi:10.1128/MCB.25.8.2957–2968.2005.

45. Hsu SM, Chen YC, Jiang MC (2000) 17 beta-estradiol inhibits tumor necrosis factor-alpha-induced nuclear factor-kappaB activation by increasing nuclear factor-kappa B p105 level in MCF-7 breast cancer cells. Biochem Biophys Res Commun 279: 47–52. doi:10.1006/bbrc.2000.3191.

46. Tafani M, Pucci B, Russo A, Schito L, Pellegrini L, et al. (2013) Modulators of HIF-1 alpha and NFkappaB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? Frontiers in Pharmacology 4. Available: http://www.frontierin.org/Pharmacology_of_Anti-Cancer_Drugs/10.3389/fphar.2013.00013/abstract. Accessed 24 February 2013.

47. Caldon CE, Lee CSL, Sutherland RL, Masgrove EA (2008) Wilms’ tumor protein 1: an early target of progestin regulation in T47D breast cancer cells that modulates proliferation and differentiation. Oncogene 27: 126–138. doi:10.1038/jnjc.201210622.

48. Han Y, Yang L, Suarez-Suaita F, San-Marina S, Cui J, et al. (2008) Wilms’ tumor protein 1 suppressor gene mediates antioestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells. Mol Cancer Res 6: 1347–1355. doi:10.1158/1541–7786.MCR-07–2179.

49. Quintana AM, Liu F, O’Rourke JP, Neus SA (2011) Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer 11: 30. doi:10.1186/1471–2407–11–30.

50. Wellborn WJ, Stunnenberg HG, Sweep FCGJ, Span PN (2007) Identifying estrogen receptor target genes. Mol Oncol 1: 138–143. doi:10.1016/j.molonc.2007.04.001.

51. Bhata-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, et al. (2009) Estrogen-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 37: 4850–4861. doi:10.1093/nar/gkp500.

52. Ray S, Pollard JW (2012) KLF15 negatively regulates estrogen-induced epidermal cell proliferation by inhibition of DNA replication licensing. Proc Natl Acad Sci USA 109: E1334–1343. doi:10.1073/pnas.1118515109.

53. Fouge`re M, Gaudineau B, Barbier J, Guaddachi F, Feugeas J-P, et al. (2010) NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene 29: 2292–2301. doi:10.1038/onc.2009.499.

54. Gilles C, Polente M, Riembaut P, Bruinier N, Thompson DW (1997) Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 15: 519–526.